New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2013
12:45 EDTCYH, POT, IPI, AGU, HLF, COH, MRK, PFE, AET, OSK, WU, PBI, HMA, MOSOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as a report on rising home prices along with some better than expected earnings reports supported the market. The second quarter earnings season, which is reaching its peak this week, may not be turning out to be as bad as some had feared. However, the week's biggest events may still be yet to come, as investors brace for tomorrow's conclusion of the Fedís two day FOMC meeting, along with the latest monthly jobs report, due Friday. ECONOMIC EVENTS: In the U.S., the S&P/Case-Shiller 20-city home-price index was up 12.2% from the prior year and was up about 1.0% from the prior month in May, which was close to in line with forecasts. The consumer confidence index for July fell to 80.3, which was a bit worse than the expectation for it to slip just slightly from its prior reading of 81.4. COMPANY NEWS: Several of the day's worst performing stocks were fertilizer companies after Russian potash producer Uralkali ended its cooperation with Belarus' Belaruskali. Following the news, Potash (POT) tumbled 20%, Mosaic (MOS) plunged 19%, Intrepid Potash (IPI) plummeted 30%, and Agrium (AGU) dropped nearly 5%... Among several notable healthcare names to announce quarterly results this morning, Pfizer (PFE) performed the best, rising almost 1% following its report. Its peer, Merck (MRK), slid about 1% after its own report, while health insurer Aetna (AET) was little changed in midday trade. MAJOR MOVERS: Among the notable gainers following their earnings reports were Oshkosh (OSK), up 12%, Pitney Bowes (PBI), up 11%, and Western Union (WU), up 9%. Shares of multi-level marketer Herbalife (HLF) also rose over 4% following its report in spite of new questions from Bill Ackman's Pershing Square, which has a very large and well documented short position in the stock. Among the noteworthy losers was upscale accessories maker Coach (COH), which fell more than 7% after the company reported mixed fourth quarter results, announced the departure of two senior executives, and agreed to sell its Reed Krakoff business. Also lower were shares of hospital chain Health Management Associates (HMA), which fell 11% after Community Health (CYH) agreed to buy the company for the equivalent of about $13.78 per share plus possible future considerations based on the outcome of certain legal matters. INDICES: Near noon, the Dow was up 10.37, or 0.07%, to 15,532.34; the Nasdaq was up 23.81, or 0.66%, to 3,622.95; and the S&P 500 was up 3.18, or 0.19%, to 1,688.51.
News For CYH;HMA;PBI;WU;OSK;AET;PFE;MRK;COH;HLF;AGU;IPI;POT;MOS From The Last 14 Days
Check below for free stories on CYH;HMA;PBI;WU;OSK;AET;PFE;MRK;COH;HLF;AGU;IPI;POT;MOS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 16, 2014
11:46 EDTHLFHerbalife August volatility flat into Q2
Subscribe for More Information
10:59 EDTHLFHerbalife August volatility flat on into Q2
Subscribe for More Information
10:51 EDTCYHHospitals advance after HCA preliminary results beat expectations
Shares of a number of hospital stocks are rising after one of the companies in the sector, HCA Holdings (HCA), preannounced stronger than expected second quarter results. WHAT'S NEW: HCA Holdings estimated that its Q2 EPS would come in at $1.07, versus analysts' consensus forecast of 92c. The hospital operator estimated that its Q2 revenue would be $9.23B, versus the consensus estimate of $8.86B. Moreover, HCA hiked its fiscal 2014 EPS guidance, excluding certain items, to $4.00-$4.25 from its prior view of $3.45-$3.75. The company added that its same facility admissions had risen 1.2% during Q2 versus the same period a year earlier, while same facility revenue per equivalent admission is expected to jump about 5.4%. ANALYST REACTION: In a note to investors earlier today, Wells Fargo analyst Gary Lieberman stated that it's possible that the Affordable Care Act was responsible for most of the amount by which the company's EPS beat the consensus outlook. As a result, he thinks that the company's full-year guidance appears "rather conservative." The analyst kept an Outperform rating on HCA shares. PRICE ACTION: In mid-morning trading, Community Health (CYH) surged 8% to $46, Tenet (THC) rallied 7.5% to $48.33, Universal Health (UHS) climbed 5% to $96.44, and LifePoint (LPNT) advanced 6% to $65.06, and HCA Holdings gained 7.8% to $59.50.
10:36 EDTPFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:17 EDTHLFAckman to detail Herbalife club probe next week, NY Post says
Subscribe for More Information
10:00 EDTPOTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:59 EDTCYHHCA Holdings guidance increase looks conservative, says Wells Fargo
Subscribe for More Information
09:35 EDTCYHHospitals rally after HCA Holdings boosts outlook
After HCA Holdings (HCA) raised its outlook for the year, peers Community Health (CYH), Tenet (THC), Universal Health (UHS) and LifePoint Hospitals (LPNT) are strongly to the upside in early trading.
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
09:13 EDTAGUCleveland Research sees risk to Agrium 2H and FY15 Street estimates
Subscribe for More Information
07:59 EDTPFETreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:21 EDTPOTPotash downgraded to Hold from Buy at TD Securities
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
17:03 EDTWUWestern Union names Raj Agrawal as CFO, executive VP
Subscribe for More Information
12:31 EDTCOHMichael Kors sinks after analysts issue bearish notes
Subscribe for More Information
11:13 EDTMRKPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 11, 2014
18:06 EDTCYHCommunity Health to acquire Natchez, Mississippi hospital
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use